Visual and treatment outcomes of tubercular uveitis: a prospective case series from a referral hospital in Pakistan.
Anti tuberculous treatment
Ocular TB
Tuberculous uveitis
Uveitis
Journal
BMC research notes
ISSN: 1756-0500
Titre abrégé: BMC Res Notes
Pays: England
ID NLM: 101462768
Informations de publication
Date de publication:
15 Jul 2019
15 Jul 2019
Historique:
received:
24
04
2019
accepted:
05
07
2019
entrez:
17
7
2019
pubmed:
17
7
2019
medline:
7
1
2020
Statut:
epublish
Résumé
Pakistan is the fifth highest TB burden country. Tuberculous uveitis (TbU) is a form of extrapulmonary TB, that is not uncommon in high burden country but very limited data is available on its outcome. The aim of the study is to assess the outcome of TbU with anti-tuberculous treatment (ATT). A prospective study was conducted at Jinnah Medical College Hospital (JMCH) Karachi, Pakistan from July to December 2017. Patients with suspected TbU were started on standard ATT chemotherapy for 12 months. Their response was assessed via slit lamp examination and visual acuity at 1, 3, 6 and 12 months of treatment. Forty patients with probable TbU were treated with ATT, mean age was 36 ± 3 years and 24 (60%) were females. Around 26 (65%) had Monteux test of 15 mm or more. History of TB contact was positive in 24 (60%) and 12 (30%) had previous history of TB. All patients complained for blurring of vision and floaters. Posterior uveitis seen in 36 (90%) of patients. Complete response achieved in 32 (80%) after ATT while 6 (14%) had changed in inflammation and 2 (6%) had no benefit.
Identifiants
pubmed: 31307549
doi: 10.1186/s13104-019-4432-8
pii: 10.1186/s13104-019-4432-8
pmc: PMC6628470
doi:
Substances chimiques
Antitubercular Agents
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
404Références
Am J Ophthalmol. 2005 Sep;140(3):509-16
pubmed: 16196117
Eye (Lond). 2006 Sep;20(9):1068-73
pubmed: 16215543
Arch Ophthalmol. 2006 Dec;124(12):1777-9
pubmed: 17159041
Int Ophthalmol. 2009 Apr;29(2):67-74
pubmed: 17486298
Surv Ophthalmol. 2007 Nov-Dec;52(6):561-87
pubmed: 18029267
Int Ophthalmol. 2008 Dec;28(6):413-23
pubmed: 18034214
Int J Infect Dis. 2009 Jul;13(4):432-5
pubmed: 19386531
Middle East Afr J Ophthalmol. 2009 Oct;16(4):188-201
pubmed: 20404986
Ophthalmology. 2011 Apr;118(4):772-7
pubmed: 21055814
Eye (Lond). 2011 Apr;25(4):475-80
pubmed: 21293496
Am J Ophthalmol. 2011 Sep;152(3):433-440.e1
pubmed: 21652022
J Pak Med Assoc. 2012 Feb;62(2):92-7
pubmed: 22755365
Int J Infect Dis. 2013 Nov;17(11):e993-9
pubmed: 23706496
Middle East Afr J Ophthalmol. 2014 Oct-Dec;21(4):291-5
pubmed: 25371632
Clin Ophthalmol. 2015 Nov 26;9:2223-7
pubmed: 26648690